Stonegate Healthcare's research approach centers on conducting a thorough comparative analysis to identify potentially revolutionary assets and technologies.
Dallas, Texas--(Newsfile Corp. - July 13, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in RNA Therapeutics. The report, The RNA Revolution: Unleashing the Therapeutic Potential of RNAi, highlights the potential of RNA therapeutics and companies leveraging RNAi technologies are in particular focus as we believe this will be a meaningful area of development.
To view the full announcement, including downloadable images, bios, and more, click here.
- The report covers over 30 companies, highlighted companies include Alnylam, Ionis, Laronde, TME Pharma, and Transcode Therapeutics (NASDAQ: RNAZ) among others.
- The report covers the major areas of RNA therapeutics highlighting innovative and undervalued companies focused on developing RNAi, mRNA, and Aptamer technologies.
About Stonegate Healthcare
The Stonegate Healthcare mission is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development, and Investor Outreach. The firm's research approach revolves around conducting comprehensive comparative analyses in specific medical fields in order to identify assets and technologies with the highest disruptive potential. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, enabling a current understanding of emerging disruptive technologies.
Stonegate Healthcare Partners
Source: Stonegate Healthcare Partners (SHP)
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/173418